

## Special Issue

# Next-Generation Sequencing Technologies in Solid Tumor

### Message from the Guest Editor

The application of next-generation sequencing (NGS) technologies in investigations of solid tumors has allowed us to obtain the maximum genomic evaluation of the tumor. Furthermore, the application of NGS technologies on the genome/exome of affected subjects and with a positive family history of cancer has allowed the identification of a large number of genes responsible for familial/hereditary forms of cancer. NGS approaches involve DNA and RNA analysis. DNA sequencing deals with revealing nucleotide variants on a selection of genes of interest for a specific tumor area. RNA sequencing allows detection of alternative genetic transcripts, post-transcriptional modifications, gene fusion, single nucleotide mutations/polymorphisms, small and long non-coding RNAs, and changes in gene expression. Most of the applications are in the field of cancer research, but NGS technology is also widely used in molecular diagnostics. In this Special Issue, we would like to collect recent diagnostic/predictive clinical findings obtained from NGS applications to various solid tumors and on the genome/germline exome of subjects affected by familial/hereditary cancers.

### Guest Editor

Dr. Francesca Duraturo

Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy

### Deadline for manuscript submissions

closed (31 December 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/102027](https://mdpi.com/si/102027)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).